Abstract
Subclinical antibody-mediated rejection is defined as the presence of circulating donor HLA specific antibodies with the presence of typical pathological finding of antibody-mediated rejection and no change in graft function. It is known to be associated with poor outcome. Bortezomib is a proteasome inhibitor which has been used recently in treatment of antibody mediated rejection with varying degrees of success. It acts on antibodies producing plasma cells. It is commonly used with intravenous immunoglobulin infusion, therapeutic plasma exchange and rituximab and prednisone.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
